Novo Nordisk Q2 2026 earnings beat, raises full-year outlook - qz.com
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Novo Nordisk reported Q2 2026 earnings that beat analyst forecasts and raised its full-year outlook, with the company crediting soaring GLP-1 sales.
- Despite the beat-and-raise headline, Novo Nordisk shares slid — WSJ pinning the drop on a Wegovy shortfall and CNBC reporting the updated guidance disappointed investors.
Why it matters: Even with an earnings beat and a raised full-year outlook, shares fell — WSJ cited a Wegovy shortfall and CNBC flagged the guidance as a disappointment. The split reaction shows investors now weigh Wegovy volume and forward-momentum commentary more than the headline EPS print for GLP-1 leaders.
